Semaglutide is a revolutionary GLP-1 receptor agonist that was originally developed for patients with Type 2 diabetes, but when providers and pharmaceutical developers noticed how much weight their patients were losing, they began to study semaglutide exclusively for weight loss. A series of clinical trials known as the STEP clinical trials demonstrated that almost 90% of patients lost 5% or more of their body weight. In june of 2022, the FDA approved semaglutide for weight loss. Semaglutide increases insulin production, decreases glucagon synthesis, delays gastric emptying and suppresses hunger. It signals your brain that you are full so you can lose weight without feeling like you are depriving yourself.